TXG as reported
10x Genomics, Inc. reported $639M of revenue over the trailing twelve months, +2.3% on the year before. 10 reported series are charted on this page, each one as filed.
$639M
Revenue, trailing twelve months · to Q1 2026 · +2.3% against the twelve months before
- Net Income
- −$23M
Net Income · −86% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $122M
Free Cash Flow · +169% year on year · trailing twelve months to Q1 2026
- Op Margin
- −6.8%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $639M | +2.3% | Q1 2026 |
| Net Income | −$23M | −86% | Q1 2026 |
| EPS | −$0.17 | −87% | Q1 2026 |
| Gross Margin | 70% | n/a | Q1 2026 |
| Op Margin | −6.8% | n/a | Q1 2026 |
| Net Margin | −4.3% | n/a | Q1 2026 |
| ROE | −7.2% | n/a | Q1 2026 |
| ROA | −5.6% | n/a | Q1 2026 |
| ROIC | 257% | n/a | Q4 2020 · 21 quarters behind |
| Free Cash Flow | $122M | +169% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
10x Genomics, Inc. (TXG) - Revenue & ProfitRevenue & Profit10x Genomics, Inc. (TXG)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Health Information Services
Ranks #2 of 14 by Smart Score